|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01BA04
|
|
gptkbp:CASNumber
|
137281-23-3
|
|
gptkbp:chemicalFormula
|
C20H21N5O6
|
|
gptkbp:combines
|
gptkb:cisplatin
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:genericName
|
gptkb:pemetrexed
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alimta
|
|
gptkbp:inhibitedBy
|
dihydrofolate reductase
glycinamide ribonucleotide formyltransferase
thymidylate synthase
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
antifolate chemotherapy agent
|
|
gptkbp:patentExpired
|
2022 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
rash
neutropenia
mucositis
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
malignant pleural mesothelioma
|
|
gptkbp:bfsParent
|
gptkb:礼来
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
5
|